论文部分内容阅读
探讨增殖细胞核抗原（ＰＣＮＡ）在乳腺癌不同阶段的表达情况及其与预后的关系。方法对１９８８年９７例手术治疗的浸润性乳腺癌，以及１９８４～１９９２年间手术治疗的１３例导管内癌（ＤＣＩＳ）、６例导管内癌伴早期浸润（ＤＣＩＳ＋Ｃａ），６例导管上皮高度增生（ＰＢＤ）的原发灶进行增殖细胞核抗原（ＰＣＮＡ）免疫组织化学法检测，结合临床资料、ｃ－ｅｒｂＢ－２、ｐ５３表达情况，分析各因素之间的关系，并对９７例浸润性乳腺癌患者进行预后因素分析。结果浸润性乳腺癌与ＤＣＩＳ、ＰＢＤ相比，有较高的ＰＣＮＡ阳性细胞标记指数（ＰＣＮＡＬＩ）（Ｐ＜０．０５）。在ＤＣＩＳ与ＰＢＤ两组患者中，ＰＣＮＡＬＩ无差别（Ｐ＞０．０５）。在乳腺癌患者预后的单因素分析中，高ＰＣＮＡＬＩ指数的无病生存率低（Ｐ＜０．０５）；在多因素分析中，淋巴结转移情况、肿块大小、ＰＣＮＡＬＩ、ｃ－ｅｒｂＢ－２是独立的预后指标。结论ＰＣＮＡＬＩ随着恶性程度增加而升高，是一个新的乳腺癌预后指标。
To investigate the expression of proliferating cell nuclear antigen (PCNA) in different stages of breast cancer and its relationship with prognosis. Methods 97 cases of invasive breast cancer treated by surgery in 1988, 13 cases of intraductal carcinoma (DCIS) treated surgically between 1984 and 1992, 6 cases of intraductal carcinoma with early infiltration (DCIS+Ca), and 6 cases of ductal epithelial hyperplasia ( The primary tumors of PBD were detected with proliferating cell nuclear antigen (PCNA) immunohistochemical method. Combined with clinical data, c-erbB-2, p53 expression, the relationship between the factors was analyzed and 97 patients with invasive breast cancer were examined. Perform prognostic factor analysis. Results Compared with DCIS and PBD, invasive breast cancer had higher PCNA-positive cell marker index (PCNALI) (P<0.05). There was no difference in PCNALI between DCIS and PBD patients (P>0.05). In the univariate analysis of prognosis of breast cancer patients, the disease-free survival rate of high PCNALI index was low (P<0.05); in multivariate analysis, lymph node metastasis, tumor size, PCNALI, c-erbB-2 were independent The prognosis indicator. Conclusion PCNALI increases with the increase of malignancy and is a new prognostic indicator of breast cancer.